DRUG IMPLICATIONS AT THE HEPATIC LEVEL IN PATIENTS SUBMITTED TO COVID-19 TREATMENT

Detalhes bibliográficos
Autor(a) principal: Ribeiro, Elielson Antunes
Data de Publicação: 2023
Outros Autores: Bellaver, Emyr Hiago, Zancanaro, Vilmair
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista UniVap (online)
Texto Completo: https://revista.univap.br/index.php/revistaunivap/article/view/4473
Resumo: The COVID-19 virus has brought to light a new illness that has raised several questions worldwide, one of which is related to the prophylaxis of the disease, i.e., which drugs can be used to treat the infected patient and what long-term side effects the patient may develop. The aim of the article is to analyze possible hepatic changes in patients undergoing COVID-19 prophylaxis in the ICU, identify the correlation with pharmacological choice, and evaluate long-term side effects. The research was conducted by analyzing electronic medical records of 101 patients undergoing COVID-19 prophylaxis in the ICU in 2020 and 2021. The main observed hepatic changes were in GGT and AST, with the most used medication in the COVID-19 cocktail being azithromycin, associated or not with hydroxychloroquine, ivermectin, or both. The research has some limitations, as it was conducted in only one hospital unit, and therefore, the results cannot be generalized to other regions. However, the significant findings highlight the importance of evaluating the long-term side effects of medications used in COVID-19 prophylaxis, especially in relation to the liver, and considering the correlation with pharmacological choice. This can help improve therapy and prevent serious complications in patients with COVID-19
id UNIVAP-1_da04b934817e60d4d3a7458d79198031
oai_identifier_str oai:ojs.biblioteca.univap.br:article/4473
network_acronym_str UNIVAP-1
network_name_str Revista UniVap (online)
repository_id_str
spelling DRUG IMPLICATIONS AT THE HEPATIC LEVEL IN PATIENTS SUBMITTED TO COVID-19 TREATMENTIMPLICAÇÕES MEDICAMENTOSAS A NÍVEL HEPÁTICO EM PACIENTES SUBMETIDOS A TRATAMENTO DA COVID-19coronavírushepatite medicamentosaenfermeiroUTICoronavírusHepatite medicamentosacoronavirusdrug hepatitisnurseICUcoronavirusdrug hepatitisThe COVID-19 virus has brought to light a new illness that has raised several questions worldwide, one of which is related to the prophylaxis of the disease, i.e., which drugs can be used to treat the infected patient and what long-term side effects the patient may develop. The aim of the article is to analyze possible hepatic changes in patients undergoing COVID-19 prophylaxis in the ICU, identify the correlation with pharmacological choice, and evaluate long-term side effects. The research was conducted by analyzing electronic medical records of 101 patients undergoing COVID-19 prophylaxis in the ICU in 2020 and 2021. The main observed hepatic changes were in GGT and AST, with the most used medication in the COVID-19 cocktail being azithromycin, associated or not with hydroxychloroquine, ivermectin, or both. The research has some limitations, as it was conducted in only one hospital unit, and therefore, the results cannot be generalized to other regions. However, the significant findings highlight the importance of evaluating the long-term side effects of medications used in COVID-19 prophylaxis, especially in relation to the liver, and considering the correlation with pharmacological choice. This can help improve therapy and prevent serious complications in patients with COVID-19O vírus causador da COVID-19 trouxe à tona uma nova enfermidade que ocasionou diversas dúvidas a nível mundial, uma delas está relacionada à profilaxia e aos efeitos colaterais da doença, ou seja, quais fármacos poderiam ser utilizados para tratar o paciente adoecido e quais os efeitos colaterais a longo prazo que o cliente poderia ter desenvolvido. O objetivo do artigo é analisar as possíveis alterações em nível hepático em pacientes submetidos à profilaxia da COVID-19 em UTI, identificando a correlação com a escolha farmacológica e avaliando os efeitos colaterais a longo prazo. A metodologia da pesquisa foi realizada por meio da análise dos prontuários eletrônicos de 101 pacientes submetidos à profilaxia da COVID-19 em UTI, nos anos de 2020 e 2021. As principais alterações hepáticas observadas foram em GGT e AST, sendo que o medicamento mais utilizado no coquetel COVID foi a azitromicina associada ou não a hidroxicloroquina, ivermectina ou ambos. Os resultados da pesquisa tiveram algumas limitações, uma vez que foi realizada em apenas uma unidade hospitalar, portanto, os resultados não podem ser generalizados para outras regiões. No entanto, os achados significativos destacam a importância de avaliar os efeitos colaterais a longo prazo dos medicamentos utilizados na profilaxia da COVID-19, especialmente em relação ao fígado, e considerar a correlação com a escolha farmacológica. Isso pode ajudar na melhoria da terapia e na prevenção de complicações graves em pacientes com COVID-19IBICT2023-12-08info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontextoinfo:eu-repo/semantics/otherapplication/pdfhttps://revista.univap.br/index.php/revistaunivap/article/view/447310.18066/revistaunivap.v29i64.4473Revista Univap; Vol. 29 No. 64 (2023): Revista UnivapRevista Univap; v. 29 n. 64 (2023): Revista Univap2237-17531517-327510.18066/revistaunivap.v29i64reponame:Revista UniVap (online)instname:Universidade do Vale do Paraíba (Univap)instacron:UNIVAPporhttps://revista.univap.br/index.php/revistaunivap/article/view/4473/2271português Copyright (c) 2023 Revista Univaphttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessRibeiro, Elielson AntunesBellaver, Emyr HiagoZancanaro, Vilmair2023-12-08T14:16:23Zoai:ojs.biblioteca.univap.br:article/4473Revistahttps://revista.univap.br/index.php/revistaunivapPRIhttps://revista.univap.br/index.php/revistaunivap/oairevista@univap.br2237-17532237-1753opendoar:2023-12-08T14:16:23Revista UniVap (online) - Universidade do Vale do Paraíba (Univap)false
dc.title.none.fl_str_mv DRUG IMPLICATIONS AT THE HEPATIC LEVEL IN PATIENTS SUBMITTED TO COVID-19 TREATMENT
IMPLICAÇÕES MEDICAMENTOSAS A NÍVEL HEPÁTICO EM PACIENTES SUBMETIDOS A TRATAMENTO DA COVID-19
title DRUG IMPLICATIONS AT THE HEPATIC LEVEL IN PATIENTS SUBMITTED TO COVID-19 TREATMENT
spellingShingle DRUG IMPLICATIONS AT THE HEPATIC LEVEL IN PATIENTS SUBMITTED TO COVID-19 TREATMENT
Ribeiro, Elielson Antunes
coronavírus
hepatite medicamentosa
enfermeiro
UTI
Coronavírus
Hepatite medicamentosa
coronavirus
drug hepatitis
nurse
ICU
coronavirus
drug hepatitis
title_short DRUG IMPLICATIONS AT THE HEPATIC LEVEL IN PATIENTS SUBMITTED TO COVID-19 TREATMENT
title_full DRUG IMPLICATIONS AT THE HEPATIC LEVEL IN PATIENTS SUBMITTED TO COVID-19 TREATMENT
title_fullStr DRUG IMPLICATIONS AT THE HEPATIC LEVEL IN PATIENTS SUBMITTED TO COVID-19 TREATMENT
title_full_unstemmed DRUG IMPLICATIONS AT THE HEPATIC LEVEL IN PATIENTS SUBMITTED TO COVID-19 TREATMENT
title_sort DRUG IMPLICATIONS AT THE HEPATIC LEVEL IN PATIENTS SUBMITTED TO COVID-19 TREATMENT
author Ribeiro, Elielson Antunes
author_facet Ribeiro, Elielson Antunes
Bellaver, Emyr Hiago
Zancanaro, Vilmair
author_role author
author2 Bellaver, Emyr Hiago
Zancanaro, Vilmair
author2_role author
author
dc.contributor.author.fl_str_mv Ribeiro, Elielson Antunes
Bellaver, Emyr Hiago
Zancanaro, Vilmair
dc.subject.por.fl_str_mv coronavírus
hepatite medicamentosa
enfermeiro
UTI
Coronavírus
Hepatite medicamentosa
coronavirus
drug hepatitis
nurse
ICU
coronavirus
drug hepatitis
topic coronavírus
hepatite medicamentosa
enfermeiro
UTI
Coronavírus
Hepatite medicamentosa
coronavirus
drug hepatitis
nurse
ICU
coronavirus
drug hepatitis
description The COVID-19 virus has brought to light a new illness that has raised several questions worldwide, one of which is related to the prophylaxis of the disease, i.e., which drugs can be used to treat the infected patient and what long-term side effects the patient may develop. The aim of the article is to analyze possible hepatic changes in patients undergoing COVID-19 prophylaxis in the ICU, identify the correlation with pharmacological choice, and evaluate long-term side effects. The research was conducted by analyzing electronic medical records of 101 patients undergoing COVID-19 prophylaxis in the ICU in 2020 and 2021. The main observed hepatic changes were in GGT and AST, with the most used medication in the COVID-19 cocktail being azithromycin, associated or not with hydroxychloroquine, ivermectin, or both. The research has some limitations, as it was conducted in only one hospital unit, and therefore, the results cannot be generalized to other regions. However, the significant findings highlight the importance of evaluating the long-term side effects of medications used in COVID-19 prophylaxis, especially in relation to the liver, and considering the correlation with pharmacological choice. This can help improve therapy and prevent serious complications in patients with COVID-19
publishDate 2023
dc.date.none.fl_str_mv 2023-12-08
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
texto
info:eu-repo/semantics/other
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://revista.univap.br/index.php/revistaunivap/article/view/4473
10.18066/revistaunivap.v29i64.4473
url https://revista.univap.br/index.php/revistaunivap/article/view/4473
identifier_str_mv 10.18066/revistaunivap.v29i64.4473
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://revista.univap.br/index.php/revistaunivap/article/view/4473/2271
dc.rights.driver.fl_str_mv Copyright (c) 2023 Revista Univap
https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2023 Revista Univap
https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.coverage.none.fl_str_mv português
dc.publisher.none.fl_str_mv IBICT
publisher.none.fl_str_mv IBICT
dc.source.none.fl_str_mv Revista Univap; Vol. 29 No. 64 (2023): Revista Univap
Revista Univap; v. 29 n. 64 (2023): Revista Univap
2237-1753
1517-3275
10.18066/revistaunivap.v29i64
reponame:Revista UniVap (online)
instname:Universidade do Vale do Paraíba (Univap)
instacron:UNIVAP
instname_str Universidade do Vale do Paraíba (Univap)
instacron_str UNIVAP
institution UNIVAP
reponame_str Revista UniVap (online)
collection Revista UniVap (online)
repository.name.fl_str_mv Revista UniVap (online) - Universidade do Vale do Paraíba (Univap)
repository.mail.fl_str_mv revista@univap.br
_version_ 1797042284705873920

Registros relacionados